

Charis Pericleous

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1822740/charis-pericleous-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41
papers

1,017
citations

15
h-index

31
g-index

44
ext. papers

1,198
ext. citations

5.4
avg, IF

3.69
L-index

#	Paper	IF	Citations
41	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome.. <i>Frontiers in Immunology</i> , 2022 , 13, 842923	8.4	
40	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , 2021 , 60, 1376-1386	3.9	4
39	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EClinicalMedicine</i> , 2021 , 39, 101070	11.3	7
38	Identification of a Novel HIF-1 α -Integrin-NET Axis in Fibrotic Interstitial Lung Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 2190	8.4	6
37	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020 , 39, 100610	11.1	42
36	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020 , 59, 146-152	3.9	6
35	Domain I of β GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. <i>Lupus</i> , 2019 , 28, 893-897	2.6	1
34	Autoimmune rheumatic disease IgG has differential effects upon neutrophil integrin activation that is modulated by the endothelium. <i>Scientific Reports</i> , 2019 , 9, 1283	4.9	7
33	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 93, 114-123	15.5	13
32	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018 , 9, 2413	8.4	8
31	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018 , 9, 2244	8.4	8
30	Oxidation of β -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017 , 12, e0186513	3.7	8
29	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. <i>Cell Death and Disease</i> , 2017 , 8, e2549	9.8	13
28	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017 , 7, 10788	4.9	5
27	The association between IgG and IgM antibodies against cardiolipin, β -glycoprotein I and Domain I of β -glycoprotein I with disease profile in patients with multiple sclerosis. <i>Molecular Immunology</i> , 2016 , 75, 161-7	4.3	12
26	Measuring IgA Anti- β -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0156407	3.7	50
25	Longer duration of B cell depletion is associated with better outcome. <i>Rheumatology</i> , 2015 , 54, 1876-81	3.9	18

24	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , 2015 , 17, 47	5.7	11
23	Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. <i>American Journal of Reproductive Immunology</i> , 2015 , 73, 390-401	3.8	22
22	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β_2 -glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , 2015 , 54, 722-7	3.9	49
21	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. <i>BMC Biotechnology</i> , 2015 , 15, 104	3.5	6
20	Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation. <i>PLoS ONE</i> , 2015 , 10, e0143771	3.7	15
19	Antibodies to domain I of β_2 -glycoprotein I and IgA antiphospholipid antibodies in patients with β_2 -glycoprotein I antibody positive antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 317-9	2.4	35
18	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2014 , 16, R48	5.7	4
17	Laboratory tests for the antiphospholipid syndrome. <i>Methods in Molecular Biology</i> , 2014 , 1134, 221-35	1.4	4
16	Domain I: the hidden face of antiphospholipid syndrome. <i>Lupus</i> , 2014 , 23, 1320-3	2.6	6
15	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 72-8	7	16
14	Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. <i>American Journal of Reproductive Immunology</i> , 2011 , 66, 286-96	3.8	58
13	Evaluating the conformation of recombinant domain I of β_2 -glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , 2011 , 49, 56-63	4.3	14
12	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β_2 -glycoprotein I. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2774-82		84
11	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3512-21		11
10	Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. <i>Journal of Immunology</i> , 2010 , 184, 6622-8	5.3	58
9	New therapeutic targets for the antiphospholipid syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2010 , 14, 1291-9	6.4	8
8	Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. <i>Journal of Immunology</i> , 2009 , 182, 4836-43	5.3	18
7	Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome?. <i>Lupus</i> , 2009 , 18, 671-5	2.6	20

6	Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. <i>American Journal of Reproductive Immunology</i> , 2009 , 62, 96-111	3.8	133
5	In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. <i>Journal of Thrombosis and Haemostasis</i> , 2009 , 7, 833-42	15.4	102
4	Do Antiphospholipid Antibodies Have Direct Pathologic Effects Upon Endometrial and Trophoblast Cells?. <i>Current Rheumatology Reviews</i> , 2009 , 5, 83-97	1.6	4
3	Gene expression studies on bio-electrosprayed primary cardiac myocytes. <i>Biotechnology Journal</i> , 2008 , 3, 530-5	5.6	15
2	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , 2007 , 56, 280-90		115
1	Identification of a novel HIF-1 α /Integrin-NETosis axis in fibrotic interstitial lung disease		1